Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Alternative Applications For Drug Delivery: Nasal And Pulmonary Routes

A. Ozer
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
For treatment of human diseases, nasal and pulmonary routes of drug delivery are gaining increasing importance. These routes provide promising alternatives to parenteral drug delivery particularly for peptide and protein therapeutics. For this purpose, several drug delivery systems have been formulated and are being investigated for nasal and pulmonary delivery. These include liposomes, proliposomes, microspheres, gels, prodrugs, cyclodextrins and others. In this chapter, nasal and pulmonary drug delivery mechanisms and some of the relevant drug delivery formulations are evaluated
This paper references
10.1208/pt030105
Targeted brain delivery of 17β-estradiol via nasally administered water soluble prodrugs
Abeer M. Al-Ghananeem (2008)
10.1001/ARCHINTE.1973.00320070105012
Alveolobronchiolar transport mechanisms.
G. Green (1973)
10.1023/A:1018908705446
Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles
R. Fernández-Urrusuno (2004)
10.1288/00005537-198507000-00022
Correlation between nasal ciliary beat frequency and mucus transport rate in volunteers
G. Duchateau (1985)
10.1023/A:1018927710280
Tolerability and Absorption Enhancement of Intranasally Administered Octreotide by Sodium Taurodihydrofusidate in Healthy Subjects
T. Kissel (2004)
10.1016/S0378-5173(00)00434-8
Intranasal bioavailability of apomorphine from carboxymethylcellulose-based drug delivery systems.
M. Ikechukwu Ugwoke (2000)
10.1248/CPB.40.3100
Enhancing effect of cyclodextrins on nasal absorption of insulin and its duration in rabbits.
Y. Watanabe (1992)
10.1016/J.JCONREL.2004.08.001
Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system.
V. Leitner (2004)
10.1152/JAPPL.1977.43.1.46
Effects of exercise and eucapnic hyperventilation on bronchial clearance in man.
R. Wolff (1977)
Technology evaluation: cystic fibrosis therapy, Genzyme.
Cockett Mi (1999)
10.1016/S0168-3659(99)00258-8
Prolonged delivery of nicotine in rats via nasal administration of proliposomes.
B. Jung (2000)
10.1016/S0378-5173(01)00602-0
Clearance characteristics of chitosan based formulations in the sheep nasal cavity.
R. Soane (2001)
10.1016/S0169-409X(97)00058-6
Anatomy, physiology and function of the nasal cavities in health and disease.
Dahl (1998)
10.1210/JCEM.76.4.8473411
Intranasal administration of human growth hormone (hGH) in combination with a membrane permeation enhancer in patients with GH deficiency: a pharmacokinetic study.
L. Hedin (1993)
10.1016/S0169-409X(97)00059-8
Nasal mucociliary clearance as a factor in nasal drug delivery.
Merkus (1998)
10.1248/CPB.40.1569
Permeability of insulin entrapped in liposome through the nasal mucosa of rabbits.
Y. Maitani (1992)
10.1023/A:1015830907632
The Nasal Mucociliary Clearance: Relevance to Nasal Drug Delivery
N. G. Schipper (2004)
10.1016/S0169-409X(97)00064-1
Optimization of systemic nasal drug delivery with pharmaceutical excipients.
Roméo (1998)
Nasal systemic drug delivery
Y. Chien (1989)
Intranasal drug delivery for systemic medications.
Y. Chien (1987)
10.1164/AJRCCM/151.3_PT_1.630
Ciliary abnormalities in bronchial epithelium of smokers, ex-smokers, and nonsmokers.
F. Verra (1995)
10.1111/j.2042-7158.1985.tb05024.x
Enhancement of nasal absorption of insulin and calcitonin using polyacrylic acid gel
K. Morimoto (1985)
10.1201/9780203910337
Modified-Release Drug Delivery Technology
M. Rathbone (2002)
10.1023/A:1018911206646
Drug Metabolism in the Nasal Mucosa
Mohamadi A. Sarkar (2004)
10.1111/j.1464-5491.1992.tb01792.x
Intranasal Administration of Insulin With Phospholipid as Absorption Enhancer: Pharmacokinetics in Normal Subjects
K. Drejer (1992)
10.3109/10611869808997878
Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs.
E. Marttin (1998)
10.1023/A:1012109329631
Confocal Laser Scanning Microscopic Visualization of the Transport of Dextrans After Nasal Administration to Rats: Effects of Absorption Enhancers
E. Marttin (2004)
10.1016/S0378-5173(03)00090-5
Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethyl-beta-cyclodextrins.
Prapasri Sinswat (2003)
10.1002/JPS.2600831212
Epithelial Transport and Bioavailability of Intranasally Administered Human Growth Hormone Formulated with the Absorption Enhancers Didecanoy‐L‐α‐phosphatidylcholine and α‐Cyclodextrin in Rabbits
C. Agerholm (1994)
10.1046/J.1365-2273.1999.00190.X
Twenty-four hour ambulatory nasal pH monitoring.
S. S. Hehar (1999)
10.1016/0378-5173(88)90236-0
Degradable starch microspheres as a nasal delivery system for insulin
E. Björk (1988)
10.1109/ICCON.1989.770491
Controlled drug delivery systems
J. Kost (1989)
The use of inhaled liposome formulations for drug delivery to the lungs and systemic circulation.
Fielding Rm (1989)
10.1211/0022357022322
Chitosan salts as nasal sustained delivery systems for peptidic drugs
T. Cerchiara (2003)
10.1016/0168-3659(90)90016-M
Nasal administration of insulin using bioadhesive microspheres as a delivery system
N. Farraj (1990)
10.1080/02652040050161765
Preparation and in vitro characterization of gelatin microspheres containing Levodopa for nasal administration.
B. Brime (2000)
10.1007/s004050100339
Prostaglandin E2 activates the ciliary beat frequency of cultured human nasal mucosa via the second messenger cyclic adenosine monophosphate
B. Haxel (2001)
10.1023/A:1018992716621
The Bioavailability of Intranasal Salmon Calcitonin in Healthy Volunteers with and Without a Permeation Enhancer
W. Lee (2004)
10.1038/sj.gt.3301212
Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis
S C Hyde (2000)
10.1081/LPR-100108460
ENHANCEMENT OF NASAL ABSORPTION OF CALCITONIN LOADED IN LIPOSOMES
S. Law (2001)
10.1201/9780203910337-64
Intranasal Drug Delivery
D. Wermeling (2002)
10.1016/0378-5173(89)90262-7
Enhanced nasal absorption of insulin in rats using lysophosphatidylcholine
L. Illum (1989)
10.1016/S0378-5173(99)00451-2
Chitosans as nasal absorption enhancers of peptides: comparison between free amine chitosans and soluble salts.
P. Tengamnuay (2000)
10.1023/A:1015896405389
Absorption Enhancing Effect of Cyclodextrins on Intranasally Administered Insulin in Rats
F. H. H. M. Merkus (2004)
10.3109/03639049109026627
Use of Chemical Enhancers for Nasal Drug Delivery
R. Ponti (1991)
10.1023/B:PHAR.0000026823.82950.ff
Nasal route and drug delivery systems
S. Türker (2004)
10.1080/02652040310001599742
Oxprenolol-loaded bioadhesive microspheres: preparation and in vitro/in vivo characterization.
M. Preda (2003)
10.1201/9780203910337-70
Pulmonary Delivery of Drugs by Inhalation
I. Gonda (2002)
10.1136/thx.48.3.287
Effect of oral bronchodilators on lung mucociliary clearance during sleep in patients with asthma.
A. Hasani (1993)
10.1016/S0169-409X(97)00060-4
Intranasal drug delivery.
Hussain (1998)
10.1097/00005537-200002010-00025
Long‐Term Use of Preservatives on Rat Nasal Respiratory Mucosa: Effects of Benzalkonium Chloride and Potassium Sorbate
J. Cho (2000)
10.1023/A:1015872617511
Effects of Absorption Enhancers on Human Nasal Tissue Ciliary Movement in Vitro
W. Hermens (2004)
10.1111/j.2042-7158.1987.tb03398.x
The effect of molecular size on the nasal absorption of water‐soluble compounds in the albino rat
A. Fisher (1987)
10.1016/0378-5173(92)90332-V
Effectiveness of liposomes as adjuvants of orally and nasally administered tetanus toxoid
H. O. Alpar (1992)
10.1211/0022357011775145
The biopharmaceutical aspects of nasal mucoadhesive drug delivery
M. I. Ugwoke (2001)
10.1038/sj.gt.3300840
The extra- and intracellular barriers to lipid and adenovirus-mediated pulmonary gene transfer in native sheep airway epithelium
C. Kitson (1999)
10.1016/J.EJPB.2003.09.006
Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice.
A. Vila (2004)
10.1016/S0168-3659(00)00258-3
Scintigraphic evaluation in rabbits of nasal drug delivery systems based on carbopol 971p((R)) and carboxymethylcellulose.
M. I. Ugwoke (2000)
10.1016/0378-5173(82)90002-3
Effect of polymers and microspheres on the nasal absorption of insulin in rats
L. Rydén (1992)
10.1248/BPB1978.12.31
Promotion of nasal absorption of insulin by glycyrrhetinic acid derivatives. I.
M. Mishima (1989)
10.1023/A:1015847604654
Cyclodextrins as Nasal Absorption Promoters of Insulin: Mechanistic Evaluations
Z. Shao (2004)
10.1248/CPB.35.3041
Nasal absorption of nifedipine from gel preparations in rats.
K. Morimoto (1987)
10.1211/0022357055227
Pharmaceutical applications of mucoadhesion for the non‐oral routes
K. Edsman (2005)
10.1016/S0169-409X(01)00166-1
Intranasal vaccination against plague, tetanus and diphtheria.
H. O. Alpar (2001)
10.1016/0378-5173(87)90216-X
Bioadhesive microspheres as a potential nasal drug delivery system
L. Illum (1987)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar